Fortis Healthcare Limited (FORTIS) — Board Meeting | 5 August 2026

· NSE 🟡 Notable Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Board approves merger of Agilus Pathlabs entities into Agilus Diagnostics
💡 Investor Takeaway
The merger consolidates diagnostics operations without cash outflow, potentially improving efficiency but adding integration complexity.

Fortis Healthcare announced that its subsidiary Agilus Diagnostics approved merging two wholly owned entities, Agilus Pathlabs Private Limited and DDRC Agilus Pathlabs Limited, into itself via a scheme of arrangement, subject to regulatory approvals and without consideration.

📄 View Original Announcement (PDF)

About Fortis Healthcare Limited (FORTIS)

Healthcare · Healthcare · Listed on NSE

Market Cap: ₹68,550.2 Cr P/E: 65.4 ROE: 10.8% ROCE: 13.3% Div Yield: 0.11%

View full FORTIS stock details →

📡 Get AI alerts when FORTIS files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track FORTIS — Free

📊 More FORTIS filings

See all FORTIS filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when FORTIS files new disclosures

Track FORTIS filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track FORTIS — Free

Free account · 2 AI queries/day